Skip Navigation

Nephrology Dialysis Transplantation 2008 23(8):i; doi:10.1093/ndt/gfn446
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


In This Issue

The first 10% of the full text of this article appears below.

An interesting editorial comment on the pro's and con's of maximal suppression of the RAAS system in patients with chronic kidney diseases concludes that the majority of patients probably attain their optimal therapeutic response at standard doses of either ACE inhibitors or ARBs or combinations of these drugs, but that a small residual group has further therapeutic benefit of high doses. Since these patients are not a priori identifiable, a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?